News | May 06, 2008

GE Licenses Spin Signal Technology to Merck

May 7, 2008 - GE Healthcare signed a nonexclusive agreement with Merck and Co. to provide spin signal technology (SST) for imaging of the lungs to help to advance respiratory treatment development, as part of GE Healthcare’s strategy to accelerate the development of new therapeutics.

GE Healthcare’s drug development strategy includes giving pharmaceutical companies access to novel molecular imaging agents to assess the impact of potential drugs in animal models and, when appropriate, human subjects.

Under terms of the agreement, Merck will be granted access to SST utilizing hyperpolarized Xenon 129 gas, a molecular imaging agent that is under investigation by GE Healthcare to provide high speed, quantitative imaging of the lung using Magnetic Resonance Imaging (MRI). GE Healthcare originally licensed this technology from Princeton University.

This technology is being evaluated to determine if it can provide more sensitive information than currently available tests on how diseased lungs function, by using xenon, a gas that can be modified with the SST to be detectable with MRI. With this technology, MRI delivers images that may provide clinical value by allowing regional imaging of disease. This information could enhance that provided by FEV1, the volume exhaled during the first second of a forced expiratory maneuver.

"Imaging the lungs has traditionally been challenging for pharmaceutical companies needing to assess the impact of developmental therapies on lung function. This agreement enables the companies involved in this collaboration to assess in real-time the effect of potential therapeutics in animal models," said Jonathan Allis, head of the Global Imaging Network at GE Healthcare.

"With cutting edge molecular diagnostic capabilities across all modalities, GE Healthcare is well positioned to work with pharmaceutical companies to tailor therapeutic assessment programs to further their drug development," said Kim Gallagher, head of External Scientific Affairs in the Medical Diagnostics Division of GE Healthcare. "By joining this development collaboration, Merck will have full access to the SST and hyperpolarized Xenon 129 trial data to monitor its potential and plan for its possible incorporation in therapy trials. We look forward to initiating further agreements with key pharmaceutical companies in the coming year in other disease areas."

For more information: www.gehealthcare. com and www.merck.com

Related Content

Youth Football Changes Nerve Fibers in Brain

Statistically significant clusters (red-colored) showing group differences (Control vs. Football) in white matter strain along the primary (F1) and secondary (F2) fibers. While body of corpus callosum (BBC) showed relative shrinkage in Football group, the other clusters showed relative stretching of fibers. PCR: Posterior Corona Radiata, PLIC: Posterior Limb of Internal Capsule, SCR: Superior Corona Radiata, SLF: Superior Longitudinal Fasciculus, SCC: Splenium of Corpus Callosum. Image courtesy of Kim et al.

News | Neuro Imaging | December 07, 2018
Magnetic resonance imaging (MRI) scans show repetitive blows to the head result in brain changes among youth football...
Siemens Healthineers Debuts Magnetom Altea 1.5T MRI Scanner
Technology | Magnetic Resonance Imaging (MRI) | December 06, 2018
During the 104th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Nov. 25-30...
GE Healthcare Unveils New Applications and Smart Devices Built on Edison Platform
Technology | Artificial Intelligence | December 05, 2018
GE Healthcare recently announced new applications and smart devices built on Edison – a platform that helps accelerate...
Snoring Poses Greater Cardiac Risk to Women
News | Women's Health | November 29, 2018
Obstructive sleep apnea (OSA) and snoring may lead to earlier impairment of cardiac function in women than in men,...
Vital Showcases Enterprise Imaging Advances at RSNA 2018

Global Illumination from Vital Images

News | Enterprise Imaging | November 28, 2018
Vital, a Canon Group company, will highlight the latest additions to its enterprise imaging portfolio at the 2018...
Artificial Intelligence May Help Reduce Gadolinium Dose in MRI

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

News | Contrast Media | November 27, 2018
Researchers are using artificial intelligence (AI) to reduce the dose of a contrast agent that may be left behind in...
Arterys Demonstrates AI Cloud-Based Medical Image Analysis Solutions at RSNA 2018
News | Computer-Aided Detection Software | November 26, 2018
Medical imaging software company Arterys will demonstrate its wide-ranging suite of artificial intelligence (AI)-...
HeartVista Announces One Click Autonomous MRI Solution
News | Magnetic Resonance Imaging (MRI) | November 25, 2018
HeartVista announced its artificial intelligence (AI)-driven, One-Click Autonomous MRI acquisition software for cardiac...
Siemens Healthineers Showcases syngo Virtual Cockpit for More Flexible Workforce Management
News | Teleradiology | November 25, 2018
During the 104th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Nov. 25-30...
Canon Medical Receives FDA Clearance for Vantage Orian 1.5T MRI
Technology | Magnetic Resonance Imaging (MRI) | November 15, 2018
Canon Medical Systems USA Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) on its new...